Today's Daily Dose brings you news about Adverum's progress on ADVM-022, a novel gene therapy candidate for the treatment of wet age-related macular degeneration; European Commission approval of Amgen's expanded indication for BLINCYTO; Bausch Health's regulatory catalyst for February and Mesoblast's fourth quarter financial results.
from RTT - Biotech https://ift.tt/2wtj4O6
via IFTTT
No comments:
Post a Comment